Hockley James R F, González-Cano Rafael, McMurray Sheridan, Tejada-Giraldez Miguel A, McGuire Cian, Torres Antonio, Wilbrey Anna L, Cibert-Goton Vincent, Nieto Francisco R, Pitcher Thomas, Knowles Charles H, Baeyens José Manuel, Wood John N, Winchester Wendy J, Bulmer David C, Cendán Cruz Miguel, McMurray Gordon
Neuroscience and Pain Research Unit, Pfizer Ltd., The Portway Building, Granta Science Park, Cambridge, CB21 6GS, UK.
Department of Pharmacology, Biomedical Research Centre (CIBM) and Institute of Neuroscience, Faculty of Medicine, University of Granada, Granada, Spain.
J Physiol. 2017 Apr 15;595(8):2661-2679. doi: 10.1113/JP272837. Epub 2017 Mar 1.
Voltage-gated sodium channels play a fundamental role in determining neuronal excitability. Specifically, voltage-gated sodium channel subtype Na 1.7 is required for sensing acute and inflammatory somatic pain in mice and humans but its significance in pain originating from the viscera is unknown. Using comparative behavioural models evoking somatic and visceral pain pathways, we identify the requirement for Na 1.7 in regulating somatic (noxious heat pain threshold) but not in visceral pain signalling. These results enable us to better understand the mechanisms underlying the transduction of noxious stimuli from the viscera, suggest that the investigation of pain pathways should be undertaken in a modality-specific manner and help to direct drug discovery efforts towards novel visceral analgesics.
Voltage-gated sodium channel Na 1.7 is required for acute and inflammatory pain in mice and humans but its significance for visceral pain is unknown. Here we examine the role of Na 1.7 in visceral pain processing and the development of referred hyperalgesia using a conditional nociceptor-specific Na 1.7 knockout mouse (Na 1.7 ) and selective small-molecule Na 1.7 antagonist PF-5198007. Na 1.7 mice showed normal nociceptive behaviours in response to intracolonic application of either capsaicin or mustard oil, stimuli known to evoke sustained nociceptor activity and sensitization following tissue damage, respectively. Normal responses following induction of cystitis by cyclophosphamide were also observed in both Na 1.7 and littermate controls. Loss, or blockade, of Na 1.7 did not affect afferent responses to noxious mechanical and chemical stimuli in nerve-gut preparations in mouse, or following antagonism of Na 1.7 in resected human appendix stimulated by noxious distending pressures. However, expression analysis of voltage-gated sodium channel α subunits revealed Na 1.7 mRNA transcripts in nearly all retrogradely labelled colonic neurons, suggesting redundancy in function. By contrast, using comparative somatic behavioural models we identify that genetic deletion of Na 1.7 (in Na 1.8-expressing neurons) regulates noxious heat pain threshold and that this can be recapitulated by the selective Na 1.7 antagonist PF-5198007. Our data demonstrate that Na 1.7 (in Na 1.8-expressing neurons) contributes to defined pain pathways in a modality-dependent manner, modulating somatic noxious heat pain, but is not required for visceral pain processing, and advocate that pharmacological block of Na 1.7 alone in the viscera may be insufficient in targeting chronic visceral pain.
电压门控钠通道在决定神经元兴奋性方面起着根本性作用。具体而言,电压门控钠通道亚型Na 1.7是小鼠和人类感知急性和炎性躯体疼痛所必需的,但它在源于内脏的疼痛中的意义尚不清楚。通过比较引发躯体和内脏疼痛途径的行为模型,我们确定了Na 1.7在调节躯体(有害热痛阈值)方面的需求,但在内脏疼痛信号传导方面并非如此。这些结果使我们能够更好地理解内脏有害刺激转导的潜在机制,表明疼痛途径的研究应以特定模式的方式进行,并有助于将药物研发工作导向新型内脏镇痛药。
电压门控钠通道Na 1.7是小鼠和人类急性和炎性疼痛所必需的,但其在内脏疼痛中的意义尚不清楚。在这里,我们使用条件性伤害感受器特异性Na 1.7基因敲除小鼠(Na 1.7)和选择性小分子Na 1.7拮抗剂PF-5198007,研究了Na 1.7在内脏疼痛处理和牵涉性痛觉过敏发展中的作用。Na 1.7小鼠对结肠内应用辣椒素或芥子油(分别是已知能引发持续性伤害感受器活动和组织损伤后致敏的刺激物)表现出正常的伤害性反应行为。在Na 1.7小鼠和同窝对照小鼠中,环磷酰胺诱导膀胱炎后也观察到正常反应。Na 1.7的缺失或阻断不影响小鼠神经-肠道制剂中对有害机械和化学刺激的传入反应,也不影响在有害扩张压力刺激下切除的人阑尾中Na 1.7拮抗后的传入反应。然而,电压门控钠通道α亚基的表达分析显示,几乎所有逆行标记的结肠神经元中都有Na 1.7 mRNA转录本,提示功能冗余。相比之下,通过比较躯体行为模型,我们发现Na 1.7(在表达Na 1.8的神经元中)的基因缺失调节有害热痛阈值,并且选择性Na 1.7拮抗剂PF-5198007可以重现这一现象。我们的数据表明,Na 1.7(在表达Na 1.8的神经元中)以模式依赖的方式参与特定的疼痛途径,调节躯体有害热痛,但在内脏疼痛处理中并非必需,并且主张仅在内脏中对Na 1.7进行药理学阻断可能不足以针对慢性内脏疼痛。